Skip to content

Amiodarone versus propafenone to treat atrial fibrillation after coronary artery bypass graft surgery

Amiodarone versus propafenone to treat atrial fibrillation after coronary artery bypass graft surgery

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT138809092795N1
Enrollment
Unknown
Registered
2011-04-16
Start date
2010-02-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation in hospitalized patients after CABG. Other postprocedural disorders of circulatory system, not elsewhere classified

Interventions

At the onset of AF, patients in second group will receive amiodarone (300mg stat and 600mg iv infusion in 12-24 hours).
Intervention 1: .At the onset of AF, patients in first group will receive propafenone (600mg PO stat and 150mg Q8h ×10 days ). Intervention 2: At the onset of AF, patients in second group will receive
Treatment - Drugs
.At the onset of AF, patients in first group will receive propafenone (600mg PO stat and 150mg Q8h ×10 days ).

Sponsors

Vice chancellor for research,Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria:All candidates for heart surgery ( on pump CABG); who fill out the consent form to participate in research. Exclusion criteria :All patients with a history of sensitivity to propafenone; 'EF <30%; cardiogenic shock; bradycardia; marked hypotension; sick sinus; electrolyte imbalance.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Treatment of atrial fibrillation after heart surgery. Timepoint: Early detection of postoperative AF will be done by the ICU nurse and will be confirmed by ICU specialist. Method of measurement: Monitoring and ECG use.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDoctor Mohammad Hassan Nemati

Shiraz University of Medical Sciences

nemati_mhs@sums.ac.ir ; Nemati_mhs@yahoo.com+98 71 1235 1090

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026